First in Human Study to Compare Safety Between Intravenous Bolus Versus Infusion of ApTOLL

NCT ID: NCT05569720

Last Updated: 2022-10-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-25
• Study Completion Date: 2022-06-24

Brief Summary

The main objective of the study is to assess the tolerability and safety of ApTOLL administration when comparing intravenous infusion vs. bolus intravenous injection, in healthy volunteers. Pharmacokinetic profile of ApTOLL will be also analysed as secondary objective of the study.

Conditions

Stroke

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ApTOLL treatment

Volunteers will receive a dose of ApTOLL of 0.1mg/kg administered intravenously as slow infusion one day and as a single bolus intravenous injection the second day. In a third and last admission day, volunteers will receive a dose of ApTOLL of 0.2mg/kg administered as a single bolus intravenous injection.

Group Type: EXPERIMENTAL

ApTOLL

Intervention Type: DRUG

ApTOLL will be administered as follows:

• Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.
• Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.
• Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection.

Interventions

ApTOLL

ApTOLL will be administered as follows:

• Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.
• Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.
• Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female (with no possibility to become pregnant (hysterectomized or menopausal women)) subjects who give their written consent to participate in the study.
• Aged from 18 to 55.
• No clinically significant organic or psychic conditions.
• No clinically significant abnormalities in medical records and physical examination.
• No clinically significant abnormalities in haematology, coagulation, biochemistry, serology and urinalysis .
• No clinically significant abnormalities in vital signs and electrocardiogram.

Exclusion Criteria

• Subjects affected by an organic or psychic condition.
• Subjects who have received prescribed pharmacological treatment in the last 15 days or any kind of medication in the 48 hours prior to receiving the study medication
• Subjects with body mass index (weight (kg)/height2 (m2)) outside the 18.5-30.0 range.
• History of sensitivity to any drug.
• Positive drug screening (for cannabis, opiates, cocaine and amphetamines).
• Smoker.
• Daily consumers of alcohol and/or acute alcohol poisoning in the last week.
• Having donated blood in the last month before start of the study.
• Participation in another study with administration of investigational drugs in the previous 3 months (if the study was conducted with drug substances marketed in Spain, a period of at least 1 month or 5 half lives, what is longer, will be considered).
• Inability to follow the instructions or collaborate during the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Centro para el Desarrollo Tecnológico Industrial

UNKNOWN

Sponsor Role: collaborator

aptaTargets S.L.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Macarena Hernández, PhD

Role: STUDY_DIRECTOR

aptaTargets S.L.

Dolores Ochoa, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario La Princesa

Locations

Clinical Pharmacology Department. Hospital Universitario de La Princesa

Madrid, , Spain

Countries

Spain

References

Hernandez-Jimenez M, Martin-Vilchez S, Ochoa D, Mejia-Abril G, Roman M, Camargo-Mamani P, Luquero-Bueno S, Jilma B, Moro MA, Fernandez G, Pineiro D, Ribo M, Gonzalez VM, Lizasoain I, Abad-Santos F. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers. Mol Ther Nucleic Acids. 2022 Mar 9;28:124-135. doi: 10.1016/j.omtn.2022.03.005. eCollection 2022 Jun 14.

Reference Type: BACKGROUND

PMID: 35402075 (View on PubMed)

Fernandez G, Moraga A, Cuartero MI, Garcia-Culebras A, Pena-Martinez C, Pradillo JM, Hernandez-Jimenez M, Sacristan S, Ayuso MI, Gonzalo-Gobernado R, Fernandez-Lopez D, Martin ME, Moro MA, Gonzalez VM, Lizasoain I. TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models. Mol Ther. 2018 Aug 1;26(8):2047-2059. doi: 10.1016/j.ymthe.2018.05.019. Epub 2018 Jun 15.

Reference Type: BACKGROUND

PMID: 29910175 (View on PubMed)

Hernandez-Jimenez M, Martin-Vilchez S, Mejia-Abril G, Roman M, Luquero-Bueno S, Pineiro D, Ribo M, Abad-Santos F, Ochoa D. Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers. Mol Ther Nucleic Acids. 2024 Dec 21;36(1):102435. doi: 10.1016/j.omtn.2024.102435. eCollection 2025 Mar 11.

Reference Type: DERIVED

PMID: 39897575 (View on PubMed)

Other Identifiers

APTABOLUS

Identifier Type: -

Identifier Source: org_study_id